Patient and doctor


We focus on developing therapies against targets where existing preclinical and early clinical data is available. This data can give a strong indication that a therapy will disrupt a targeted biochemical process and improve patient outcome without significant side-effects. Sareum’s approach is lower risk than developing therapies against entirely novel targets.

Sareum's most advanced development programme (Chk1) is undergoing two Phase 2 clinical trials, being conducted by licence partner Sierra Oncology, with a further two trials planned. The other development programmes (TYK2/JAK1 Autoimmune, TYK2/JAK1 Cancer, Aurora+FLT3) are in preclinical development.

Development Programmes Jun16

Click here for our latest research update

  • @Sareumplc Latest tweet

    RT @HybridanLLP: Good plain English article looking at the autoimmune opportunities for Tyk2 inhibitors. The @Sareumplc compounds which ar… via @Sareumplc
    View more